SOPH SOPHiA Genetics SA
Price (delayed)
$3.29
Market cap
$219.4M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.95
Enterprise value
$169.2M
sophia genetics, world's largest clinical genomics community, brings together expertise in genetics, bioinformatics, machine learning and genomic privacy. based in switzerland, we are known for our high medical standards and
Highlights
SOPHiA Genetics's EPS has increased by 22% YoY and by 13% from the previous quarter
The net income has grown by 21% YoY and by 12% from the previous quarter
SOPHiA Genetics's debt has surged by 61% YoY but it has decreased by 5% QoQ
SOPH's equity is down by 36% year-on-year and by 15% since the previous quarter
The company's quick ratio fell by 15% YoY and by 4.4% QoQ
Key stats
What are the main financial stats of SOPH
Market
Valuations
Earnings
Shares outstanding
66.69M
Market cap
$219.4M
Enterprise value
$169.2M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.27
Price to sales (P/S)
3.35
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.6
Revenue
$65.17M
Gross profit
$43.94M
Operating income
-$66.57M
Net income
-$62.49M
EBIT
-$59.36M
EBITDA
-$50.76M
Free cash flow
-$44.22M
Per share
Balance sheet
Liquidity
EPS
-$0.95
EPS diluted
-$0.95
Free cash flow per share
-$0.67
Book value per share
$1.45
Revenue per share
$0.98
TBVPS
$1.9
Total assets
$155.31M
Total liabilities
$58.82M
Debt
$30.03M
Equity
$96.49M
Working capital
$72.6M
Debt to equity
0.31
Current ratio
3.71
Quick ratio
3.27
Net debt/EBITDA
0.99
Margins
Efficiency
Dividend
EBITDA margin
-77.9%
Gross margin
67.4%
Net margin
-95.9%
Operating margin
-102.1%
Return on assets
-36%
Return on equity
-53.9%
Return on invested capital
-125.8%
Return on capital employed
-46.2%
Return on sales
-91.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
SOPH stock price
How has the SOPHiA Genetics stock price performed over time
Intraday
3.79%
1 week
-10.6%
1 month
-10.35%
1 year
-33.67%
YTD
7.17%
QTD
-0.9%
Financial performance
How have SOPHiA Genetics's revenue and profit performed over time
Revenue
$65.17M
Gross profit
$43.94M
Operating income
-$66.57M
Net income
-$62.49M
Gross margin
67.4%
Net margin
-95.9%
SOPHiA Genetics's net margin has increased by 24% YoY and by 13% QoQ
The net income has grown by 21% YoY and by 12% from the previous quarter
The operating margin has grown by 15% YoY and by 3.3% from the previous quarter
SOPH's operating income is up by 11% YoY and by 2.2% from the previous quarter
Growth
What is SOPHiA Genetics's growth rate over time
Valuation
What is SOPHiA Genetics stock price valuation
P/E
N/A
P/B
2.27
P/S
3.35
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.6
SOPHiA Genetics's EPS has increased by 22% YoY and by 13% from the previous quarter
SOPH's equity is down by 36% year-on-year and by 15% since the previous quarter
The P/B is 5% less than the last 4 quarters average of 2.3
The P/S is 21% below the last 4 quarters average of 4.1
SOPHiA Genetics's revenue has increased by 4.5% YoY
Efficiency
How efficient is SOPHiA Genetics business performance
The ROIC has grown by 37% YoY and by 20% from the previous quarter
SOPHiA Genetics's ROS has increased by 27% YoY and by 16% from the previous quarter
SOPHiA Genetics's ROE has decreased by 14% YoY but it has increased by 2.2% from the previous quarter
The ROA rose by 6% since the previous quarter
Dividends
What is SOPH's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for SOPH.
Financial health
How did SOPHiA Genetics financials performed over time
SOPH's total assets is 164% greater than its total liabilities
SOPH's total assets is down by 25% year-on-year and by 13% since the previous quarter
The company's quick ratio fell by 15% YoY and by 4.4% QoQ
SOPHiA Genetics's debt is 69% lower than its equity
The debt to equity has soared by 158% year-on-year and by 11% since the previous quarter
SOPHiA Genetics's debt has surged by 61% YoY but it has decreased by 5% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.